Zacks Investment Research·5 days ago
Revvity Expands Signals AI With Anthropic Claude IntegrationRVTY expands Signals AI through Anthropic's MCP ecosystem, giving scientists secure Claude access to connected R&D data and scientific context.
Revvity, Inc.(RVTY)Earnings, Financials & Key Ratios
RVTY•NYSE
$112.05
53.9× P/E·Price updated Jul 7, 2026
SectorHealthcareIndustryDiagnostics & ResearchSub-IndustryLife Science Instruments and Sequencing Tools
AboutRevvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.Show more
- Revenue$2.86B+3.7%
- EBITDA$659M-21.4%
- Net Income$242M-18.3%
- EPS (Diluted)2.08-13.7%
- Gross Margin53.08%+10.6%
- EBITDA Margin23.07%-24.2%
- Operating Margin12.49%-16.2%
- Net Margin8.46%-21.2%
- ROE3.24%-14.9%
RVTY Price & Volume
Revvity, Inc. (RVTY) stock price & volume — 10-year historical chart
Loading chart...
Strategic Realignment Drives Volatile Operational Performance
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Strained
Financial:Healthy
Cash Flow:Stable
Primary Risk:Newborn screening volume sensitivity
Key Thesis Takeaways
- Revvity is currently navigating a complex transition into a pure-play life sciences entity, characterized by stabilizing revenue growth of 7.0% in 2026Q1 but persistent margin pressure with operating margins at 10.7%.
- While the company has successfully reduced total debt to $3.4 billion, the significant $6.6 billion goodwill balance warrants caution regarding potential future impairment risks.
- Investors should monitor the company's ability to improve operating leverage and sustain free cash flow generation, which currently faces volatility due to ongoing integration and restructuring costs.
Verdict Logic
while the company maintains a healthy liquidity buffer with a current ratio of 1.72, the high valuation at a 54.34 P/E TTM suggests that the market has already priced in significant recovery expectations that remain unproven by current operating margins.
RVTY Growth Metrics
Revvity, Inc. (RVTY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years3.1%
5 Years-5.47%
3 Years-4.82%
TTM4.78%
Profit CAGR
10 Years1.3%
5 Years-19.79%
3 Years-24.84%
TTM-22.36%
EPS CAGR
10 Years1.04%
5 Years-20.37%
3 Years-22.69%
TTM-16.97%
Return on Capital
10 Years7.58%
5 Years5.82%
3 Years3.28%
Last Year3.16%
RVTY Recent Earnings
Revvity, Inc. (RVTY) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$1.06+3.9%
$1.02
Rev
$711M+1.0%
$704M
Q1 2026
Feb 2, 2026Metric
Actual
Est
EPS
$1.70+8.3%
$1.57
Rev
$772M+0.9%
$765M
Q4 2025
Oct 27, 2025Metric
Actual
Est
EPS
$1.18+3.5%
$1.14
Rev
$699M-0.1%
$699M
Q3 2025
Jul 28, 2025Metric
Actual
Est
EPS
$1.18+3.5%
$1.14
Rev
$720M+2.9%
$700M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $1.06vs $1.02+3.9% | $711Mvs $704M+1.0% |
| Q1 2026 | Feb 2, 2026 | $1.70vs $1.57+8.3% | $772Mvs $765M+0.9% |
| Q4 2025 | Oct 27, 2025 | $1.18vs $1.14+3.5% | $699Mvs $699M-0.1% |
| Q3 2025 | Jul 28, 2025 | $1.18vs $1.14+3.5% | $720Mvs $700M+2.9% |
Based on last 12 quarters of dataView full earnings history →
Latest RVTY News
Recent stock market news and headlines for Revvity, Inc. (RVTY)
Business Wire·Jul 1, 2026
Revvity Expands Signals AI Ecosystem Through Anthropic Claude IntegrationWALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced that its Revvity Signals Software business has joined Anthropic's directory for Model Context Protocol (MCP) connectors, enabling scientists to access Signals AI capabilities and connected R&D knowledge through Claude, including Claude Science, Anthropic's new AI workbench for scientific research. As organizations increasingly adopt artificial intelligence to accelerate scientific research, the challenge is ensuring AI mo.
Zacks Investment Research·Jun 23, 2026
Revvity Launches Signals AI to Advance Scientific R&D WorkflowsRVTY expands AI capabilities in Signals software with Signals AI, designed to help scientists turn connected R&D data into actionable insights.
Business Wire·Jun 22, 2026
Revvity Launches Signals AI, a Native Agentic Framework for Accelerating Scientific R&DWALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced the continued evolution of artificial intelligence across its Revvity Signals software business with new and expanding AI capabilities. Built natively into the Signals One™ platform, new capabilities from Signals AI help scientists transform connected R&D data into understanding, decisions and action using natural language within their existing workflows. As scientific organizations generate increasing volumes of data acr.
Peers Comparison
Key metrics vs top competitors for Revvity, Inc. (RVTY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $112.05 | $12.53B | 53.87 | 3.67% | 8.46% | 3.24% | 0.26% | |
| $374.93 | $24.44B | 34.84 | 6.99% | 11.91% | 8.04% | — | |
| $58.25 | $8.87B | -388.33 | 2.08% | -0.34% | -0.5% | — | |
| $1295.59 | $26.18B | 30.72 | 3.98% | 21.4% | — | — | |
| $292.50 | $7.9B | 10.50 | 0.65% | 6.52% | 2.4% | — | |
| $76.01 | $16.97B | 30.53 | 1.74% | 13.18% | 11.01% | — |
Compare RVTY vs Peers
Revvity, Inc. (RVTY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RVTY SEC Filings & Documents
Revvity, Inc. (RVTY) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
May 1, 2026·SEC
Material company update
Feb 2, 2026·SEC
10-K Annual Reports
210-Q Quarterly Reports
6Get notified when RVTY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RVTY Frequently Asked Questions
Revvity, Inc. (RVTY) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Revvity, Inc.'s revenue?
Revvity, Inc. (RVTY) reported $2.90B in revenue for fiscal year 2025. This represents a 103% increase from $1.43B in 1996.
How fast is Revvity, Inc. growing?
Revvity, Inc. (RVTY) grew revenue by 3.7% over the past year. Growth has been modest.
Is RVTY profitable?
Yes, Revvity, Inc. (RVTY) is profitable, generating $241.0M in net income for fiscal year 2025 (8.5% net margin).
Dividend & Returns
Does RVTY pay dividends?
Yes, Revvity, Inc. (RVTY) pays a dividend with a yield of 0.26%. This makes it attractive for income-focused investors.
What is RVTY's return on equity?
Revvity, Inc. (RVTY) has a return on equity (ROE) of 3.2%. This is below average, suggesting room for improvement.
What is Revvity, Inc.'s free cash flow?
Revvity, Inc. (RVTY) generated $504.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.